tbuckley/cabot-search huggingface dataset:
Textbook for Almoners
Journal: JAMA (1949)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Skin Permeation and Cutaneous Hypersensitivity As a Basis for Making Risk Assessments of Chromium As a Soil Contaminant
Authors: Robert E. Bagdon, Robert E. Hazen
Journal: Environmental Health Perspectives (1991)

A literature review of experimental and human exposure studies of skin permeation and cutaneous hypersensitivity reactions evoked by chromium was carried out to provide a basis for making a risk assessment of chromium as a soil contaminant.In vitro and in vivo studies demonstrated that 1 to 4% of the applied dose of hexavalent and trivalent chromium to guinea pig skin penetrated skin within 5 to 24 hr after application.Ultrastructural investigations showed that hexavalent chromium localized intracellularly and extracellularly in the upper layers of guinea pig epidermis.Only minute quantities of hexavalent chromium are required to elicit a positive hypersensitivity reaction in susceptible individuals; using a patch dose of 20 jg, only 2 jig were required to evoke a positive skin reaction in hypersensitive subjects.The potential of hexavalent chromium to produce a skin sensitization reaction is readily demonstrated using animal models.The incidence and characteristics of chromium-induced skin hypersensitivity as a clinical entity are described.A health effects survey of populations exposed to chromium slag in soil in Tokyo, Japan extending over 8 years indicated a tendency toward symptoms character- ized as headache, chronic fatigue, and gastrointestinal complaints, positive occult blood tests, minute hematuria and albuminuria suggestive of incipient renal disease, and a tendency toward an increase in contact dermatitis that was seasonally related.Multicenter patch test titration studies in human subjects using an incidence of positive patch tests of 10%X or less showed that the threshold for skin hypersensitivity reactions to hexavalent chromium was determined to be of the order 0.001%, equivalent to 10 ppm or 10 mglkg or 10 mg/L.Analysis of soil samples was conducted to predict the hexavalent chromium level from the total chromium level.Based on these data, the cleanup level of total chromium in soil is designated as 75 mg/kg.It is proposed that levels of total chromium lower than 75 mg/kg in soil would avoid undue risk of contact dermatitis.
In vitro rosetting, cytoadherence, and microagglutination properties of Plasmodium falciparum-infected erythrocytes from Gambian and Tanzanian patients
Authors: T Hasler, SM Handunnetti, JC Aguiar, MR van Schravendijk, BM Greenwood, G Lallinger, P Cegielski, RJ Howard
Journal: Blood (1990)
The Cover
Authors: —David W. Crosby
Journal: JAMA (1987)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
X-Linked Clonality Analysis and Quantitative JAK2V617F Assessment Reveals a Strong Association between Clonality and JAK2V617F in PV but Not in ET/MMM, and Identifies a Subset of JAK2V617F Negative ET and MMM Patients with Clonal Hematopoiesis.
Authors: Ross L. Levine, Claude Belisle, Martha Wadleigh, Stephanie J. Lee, Pierre Chagnon, D. Gary Gilliland, Lambert Busque
Journal: Blood (2005)
Genetic Screening
Authors: John W. Littlefield
Journal: New England Journal of Medicine (1972)

The comprehensive guidelines for genetic screening developed by the Institute of Society, Ethics and the Life Sciences, which appear elsewhere in this issue of the Journal, should certainly be required reading for anyone setting up such a program. But being primarily cautionary, they do not convey the enthusiasm many of us have for this sort of screening or its potential scope.Definition of the genetic makeup of an individual for the sake of his own health and that of his offspring is the goal of medical genetics. To illustrate how far we are from this, it suffices to note . . .
ENDOCARDIAL TUBERCULOSIS
Authors: E BARON, D W RITTER
Journal: Annals of Internal Medicine (1950)

Case Reports1 October 1950ENDOCARDIAL TUBERCULOSISEDGAR BARON, M.D., DALE W. RITTER, M.D.EDGAR BARON, M.D., DALE W. RITTER, M.D.Author, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-33-4-1023 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptInvolvement of the endocardium is one of the infrequent manifestations of tuberculosis and is usually associated with generalized miliary spread. Tuberculoma is even less common than either miliary tuberculous endocarditis or tuberculous extension from the pericardium or surrounding structure.Baker,1who wrote an excellent review of the subject in 1935, presented five cases of miliary tuberculous endocarditis and one with a tuberculoma of the right atrium associated with tuberculous pericarditis. Mark2presented a case of tuberculous endocarditis of the pulmonary valve and referred to two other cases which were reported by Davie.6Ward3described a case of miliary endocardial tuberculosis...Bibliography1. Baker RD: Endocardial tuberculosis, Arch. Path. 19: 611-635, 1948. Google Scholar2. Mark J: Tuberculous endocarditis of the pulmonary valve, Bull. Johns Hopkins Hosp. 63: 414-418, 1938. Google Scholar3. WardMartin GENH: Tuberculosis of the endocardium in a case of hypertension, Lancet 2: 826-827, 1938. Google Scholar4. BevansWilkins MSA: Tuberculous endocarditis, Am. Heart J. 24: 843-849, 1942. CrossrefGoogle Scholar5. RosenbaumLinn HHJ: Tuberculoma of the myocardium in a patient with tuberculous meningitis treated with streptomycin, Am. J. Clin. Path. 18: 162-166, 1948. CrossrefMedlineGoogle Scholar6. Davie TB: Verrucose endocarditis, J. Path. and Bact. 43: 313-320, 1936. CrossrefGoogle Scholar7. RauchweigerRogers SMRJ: Tuberculoma of the myocardium, Am. Heart J. 34: 280-283, 1947. CrossrefMedlineGoogle Scholar8. Egidio C: Tuberculosis of the aortic valve, Boll. Soc. ital. biol. sper. 3: 276, 1944. Google Scholar9. Ander JM: Tuberculosis of myocardium, J. A. M. A. 39: 1081-1086, 1902. CrossrefGoogle Scholar10. Carson WJ: Tuberculosis of the myocardium, report of additional case, M. J. and Rec. 127: 610-611, 1928. Google Scholar This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAffiliations: *Received for publication November 6, 1948.From the Department of Pathology, Veterans Administration, Kecoughtan, Virginia. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited byInsuffisance aortique aiguë d'origine tuberculeuseTuberculous aortic insufficiencyErkrankungen des EndokardHerz- und Kreislaufstörungen bei InfektionskrankheitenHerz- und Kreislaufstörungen bei Infektionskrankheiten 1 October 1950Volume 33, Issue 4Page: 1023-1030KeywordsEndocarditisEndocardiumPericardiumTuberculosis Issue Published: 1 October 1950 PDF downloadLoading ...
The Doctor-Patient Relationship in US Primary Care
Authors: Pam Lings, Philip Evans, David Seamark, Clare Seamark, Kieran Sweeney, Michael Dixon, Denis Pereira Gray
Journal: Journal of the Royal Society of Medicine (2003)

Changes in the organization of primary care in the UK are driven by a need to improve access and availability, but doctor–patient relationships may suffer. To investigate the importance of such relationships in a different setting, we analysed focus-group data obtained in a primary care facility in the USA (Rochester, NY). The findings pointed to three key factors in these relationships—namely, an asymmetry of perceptions on the two sides, belying the notion of a meeting of experts; the importance on both sides of ‘liking’; and the value set by both parties on development of trust. The last two of these factors are probably related to continuity of care, now under threat.
Information For Authors— And a Special Plea
Journal: JAMA (1973)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
A Clinical Syndrome Following Exposure to Atomic Bomb Explosions
Authors: Paul D. Keller
Journal: JAMA (1987)

The information presented in this report was obtained from studies on 21 patients who were admitted to the Osaka University Hospital in late August and early September 1945 suffering from an alarming malady designated atomic bomb disease by the Japanese. I observed, examined and followed approximately half of the patients, while information on the remaining patients was taken from the hospital records. The patients selected for presentation do not include those receiving severe blast injuries or extensive external burns at the time of the explosion. Included are patients who received minor or no injuries or burns during those catastrophic days at Hiroshima and Nagasaki but who subsequently developed severe clinical manifestations, which in 5 instances resulted in death. Seventeen of the patients herein presented experienced the atomic bombing at Hiroshima, Japan, on August 6, 1945, while the remaining 4 were victims of the Nagasaki explosion on Aug. 9, 1945. The
Abstract 3115: A single institution experience with droplet digital polymerase chain reaction (dd-PCR) liquid biopsy (LB) for therapeutic decision in advanced solid tumors
Authors: Andre Marcio Murad, José Claudio Casali-da-Rocha, Juliana Garcia Carneiro
Journal: Cancer Research (2020)

Abstract Droplet digital polymerase chain reaction (ddPCR) is a promising method for analyzing minor amounts of cell-free circulating free nucleic acid (DNA and RNA) due to its high sensitivity, low cost, and fast reading, since it dispenses bioinformatics, making it an appropriate alternative to new generation sequencing (NGS) for the detection of biomarkers to guide molecularly targeted cancer therapy. The assay covers main actionable hotspot alterations across many actionable genes: EGFR(mutations), ALK (fusion, mutations), ROS1(fusion), BRAF(mutations), KRAS (mutations), NRAS(mutations), PIK3CA (mutations), ERBB2(CNV- copy number variation), ESR1(mutations), KIT(CNV) and PDGFRA(CNV). Therefore, our genes can be used in panels, both in therapeutically applied genotyping and in detecting molecular responses as well as in secondary resistance to tumors such as NSCLC, breast, cervix. rectal, GIST, melanoma and pancreas. METHODS: dd-PCR was performed using the QX200 system (BIO-RAD®, Hercules). The extraction of DNA and RNA was done using the magnetic beads technique of Thermofisher's MagMAX Kit. All samples were tested in duplicate. 54 metastatic cancer patients were tested so far: NSCLC - 14 (26%), breast - 11 (20%), colorectal - 11 (20%), melanoma - 9(17%), pancreas - 4(7%), ovarian - 3(6%) and salivary glands - 2 (4%). RESULTS: Significant genomic alterations were detected in 19 (35%) patients: 5 (9%) mutations in the KRAS G12V gene (all in colorectal cancer), 5 (9%) ERBB2 amplification (breast cancer), 2 (3.65%) EGFR L858R mutations (NSCLC), 2 (3.5%) EGFR del19 mutations (NSLC), 2 (3.5%) EGFR T790M mutations (NSCLC), 2 (3.5%) BRAF-V600E mutations (colon and melanoma), 1 (1.8%) ALK-EML4 fusion (NSCLC). The MAF (Mutant Allele Fraction) ranged from 0.9% to 24%. In all cases, the results were decisive for the indication or change of a targeted therapy. Median turnaround time was 36 hours and the average cost of the panels was around 500 USD (median of 4 genes per panel). CONCLUSION: Our results suggest that dd-PCR is a highly sensitive method and could be used for a routine laboratory detection of the important genomic variations to determine the targeted therapy in patients with varied advanced solid tumors. Citation Format: Andre Marcio Murad, José Claudio Casali-da-Rocha, Juliana Garcia Carneiro. A single institution experience with droplet digital polymerase chain reaction (dd-PCR) liquid biopsy (LB) for therapeutic decision in advanced solid tumors [abstract]. In: Proceedings of the Annual Meeting of the American Association for Cancer Research 2020; 2020 Apr 27-28 and Jun 22-24. Philadelphia (PA): AACR; Cancer Res 2020;80(16 Suppl):Abstract nr 3115.
Incorrect Affiliations and Updated Supplement
Authors: Joseph Unger, Willliam Barlow, Dawn Hershman
Journal: JAMA Oncology (2016)

Howard I. Scher, MD; David Lu, PhD; Nicole A. Schreiber, BA; Jessica Louw, BS; Ryon P. Graf, PhD; Hebert A. Vargas, MD; Ann Johnson, MS; Adam Jendrisak, MBA; Richard Bambury, MB, BCh, BAO; Daniel Danila, MD; Brigit McLaughlin, BS; Justin Wahl, BS; Stephanie B. Greene, PhD; Glenn Heller, PhD; Dena Marrinucci, PhD; Martin Fleisher, PhD; Ryan Dittamore, MBA
Evidently.
Authors: T. H. Shastid
Journal: JAMA (1904)

Charleston, Ill., Sept. 3, 1904. <h3>To the Editor:</h3> —I notice inThe Journalfor August 27 that Dr. W. W. Keen, in a letter apropos of the educational exhibit at St. Louis, has this to say: "Next to Germany Japan has done the most. What she is doing in war she is doing in medicine." Permit me to remark that, if Japan is doing in medicine what she is doing in war, she must, indeed, be playing hades with her sick. Yours sincerely,
THE FEMALE SEX HORMONES
Journal: JAMA (1933)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Decreased atherosclerosis in CX3CR1–/– mice reveals a role for fractalkine in atherogenesis
Authors: Philippe Lesnik, Christopher A. Haskell, Israel F. Charo
Journal: Journal of Clinical Investigation (2003)

The hallmark of early atherosclerosis is the accumulation of lipid-laden macrophages in the subendothelial space. Circulating monocytes are the precursors of these "foam cells," and recent evidence suggests that chemokines play important roles in directing monocyte migration from the blood to the vessel wall. Fractalkine (FK) is a structurally unusual chemokine that can act either as a soluble chemotactic factor or as a transmembrane-anchored adhesion receptor for circulating leukocytes. A polymorphism in the FK receptor, CX3CR1, has been linked to a decrease in the incidence of coronary artery disease. To determine whether FK is critically involved in atherogenesis, we deleted the gene for CX3CR1 and crossed these mice into the apoE–/– background. Here we report that FK is robustly expressed in lesional smooth muscle cells, but not macrophages, in apoE–/– mice on a high-fat diet. CX3CR1–/– mice have a significant reduction in macrophage recruitment to the vessel wall and decreased atherosclerotic lesion formation. Taken together, these data provide strong evidence that FK plays a key role in atherogenesis.
Incorrect Author Academic Degree and Incomplete Name
Authors: Harvard Chan, Nana Keum, Marian Neuhouser, Rowan Chlebowski, Garnet Anderson
Journal: JAMA Oncology (2015)

Christopher R. Heery, MD; Nuhad K. Ibrahim, MD; Philip M. Arlen, MD; Mahsa Mohebtash, MD; James L. Murray, MD; Kimberly Koenig, MD; Ravi A. Madan, MD; Sheri McMahon, RN; Jennifer L. Marté, MD; Seth M. Steinberg, PhD; Renee N. Donahue, PhD; Italia Grenga, MD; Caroline Jochems, MD, PhD; Benedetto Farsaci, MD; Les R. Folio, DO; Jeffrey Schlom, PhD; James L. Gulley, MD, PhD
Caspase-independent commitment phase to apoptosis in activated blood T lymphocytes: reversibility at low apoptotic insult
Authors: Céline Dumont, Antoine Dürrbach, Nicolas Bidère, Matthieu Rouleau, Guido Kroemer, Ghislaine Bernard, François Hirsch, Bernard Charpentier, Santos A. Susin, Anna Senik
Journal: Blood (2000)
Biopersistence of man-made vitreous silicate fibers in the human lung
Authors: P Sébastien
Journal: Environmental Health Perspectives (1994)

There is now a substantial body of experimental data on the pulmonary biopersistence of man-made vitreous silicate fibers (MMVSF), but human data are seriously lacking.Our knowledge in this field is essentially limited to a few reports of measurements of fibers retained in lung tissue samples taken at autopsy from workers manufacturing these products.Three types of exposure were studied: fibrous glass, mineral wool, and refrac- tory ceramic fibers.Overall, the available data do not provide evidence for substantial long-term retention of fibers in the human lung after occupational exposure to MMVSF dusts.A word of caution, however; the amount of data supporting the previous statement is much greater for fibrous glass than for either mineral wool or refractory ceramic fibers.There is no human data on the key question of the kinetics of pulmonary
HEMATEMESIS AND MELENA IN CHRONIC APPENDICITIS
Journal: JAMA (1921)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
FDA gets feedback on informed consent waiver
Authors: C. Marwick
Journal: JAMA (1996)

LAST SEPTEMBER, the Food and Drug Administration (FDA) invited comment on a new proposal for exceptions from the requirement for obtaining informed consent of patients when testing new drugs or devices during medical emergencies. Now those responses are in, and while most generally support the proposal, many respondents expressed reservations and suggested changes in its details. The proposal, aimed at facilitating research while at the same time protecting the patients involved, describes how and under what circumstances exceptions from consent for this type of research could be granted when patients are unable to give consent because of their medical condition. The FDA had issued its proposal (<i>JAMA</i>. 1995;274:1184-1185) in light of increasing concerns that strict interpretation of current regulations intended to protect human subjects from research-related risks was jeopardizing certain types of studies—clinical trials of new drugs or devices used in life-threatening situations when the patients are unable to give
Science Funding
Authors: Norma C. Barfield, Patricia A. Buffler, Doyle G. Graham, Bernadette Gray-Little, Phylis Greenberger, Philip S. Guzelian, Maureen Henderson, Rogene Henderson, Lovell Jones, Michael Lieberman, Curtis A. Moore, Rafael Moure, Thomas E. Norris, Cecil B. Pikett, Macolm C. Pike, George Provenzano, Donald J. Reed, Mary Vore, I. Bernard Weinstein
Journal: Environmental Health Perspectives (1995)